title: [Acute-phase reactants and markers of inflammation in venous thromboembolic disease: correlation with clinical and evolution parameters].
abstract: OBJECTIVE
  To asses the association of acute reactants and interleukin 6 and 8 (IL-6 & IL-8) at diagnosis of venous thromboembolic disease (VTD) and clinical outcome.
  
  
  METHODS
  100 patients were diagnosed of VTD by image tests. Acute reactants (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen), D-dimer and IL-6 and IL-8 we measured at the moment of diagnosis. We made a 12 month follow-up of these patients to notice any clinical evolution outcomes (recurrences, bleeding, post-phlebitic syndrome, death).
  
  
  RESULTS
  IL-6 was increased in 9 patients and IL-8 in 3. The risk factors, time to diagnosis and pulmonary embolism rate were similar in both interleukin groups (normal and high levels). Fibrinogen levels were significantly increased in high IL-6 group (585 +/- 179 vs. 485 +/- 154 mgr/dl; p = 0.05). During follow-up there were 5 deaths, 3 recurrences, 11 bleedings and 43 postphlebitic syndromes. Normal ESR level was associated to postphlebitic syndrome (17.8 +/- 14.5 vs. 31.4 +/- 27.4 mm/1st h; p = 0.016). Patients who had high levels of IL-6 had worse survival than these with normal levels (p = 0.015).
  
  
  CONCLUSIONS
  IL-6, ESR, and CPR at diagnosis of VTD could be useful to identified patients with higher risks of death and postphlebitic syndrome during the first year after diagnosis.
authors.affiliation: Servicio de Medicina Interna, Hospital Virgen de la Luz, Cuenca. pjmy1@yahoo.es
authors.forename: P J
authors.initials: PJ
authors.lastname: Marchena Yglesias
authors.forename: J A
authors.initials: JA
authors.lastname: Nieto Rodríguez
authors.forename: S
authors.initials: S
authors.lastname: Serrano Martínez
authors.forename: O
authors.initials: O
authors.lastname: Belinchón Moya
authors.forename: A
authors.initials: A
authors.lastname: Cortés Carmona
authors.forename: A
authors.initials: A
authors.lastname: Díaz de Tuesta
authors.forename: M J
authors.initials: MJ
authors.lastname: Bruscas Alijarde
authors.forename: M D
authors.initials: MD
authors.lastname: Ruiz Ribó
mesh_terms: D000209:Acute-Phase Proteins / Q000032:analysis*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000032:analysis; D015897:Comorbidity; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D005500:Follow-Up Studies; D006801:Humans; D007249:Inflammation / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000097:blood / Q000175:diagnosis / Q000401:mortality; D011186:Postphlebitic Syndrome / Q000097:blood / Q000453:epidemiology; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D011655:Pulmonary Embolism / Q000097:blood* / Q000175:diagnosis / Q000401:mortality; D012307:Risk Factors; D013924:Thrombophlebitis / Q000097:blood* / Q000175:diagnosis / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D000209:Acute-Phase Proteins; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D015850:Interleukin-6; D016209:Interleukin-8; C036309:fibrin fragment D; D005340:Fibrinogen; D002097:C-Reactive Protein